Premium PHARMA

materialicons-round-2403
Novo Nordisk’s Weight-Loss Stumble Costs It $125 Billion (And Some Dignity)

10 days ago

Premium HEALTH CARE

materialicons-round-2403
CVS Swaps CEOs in Hopes of Riding Corporate America’s Hottest Trend

2 months ago

Premium PHARMA

materialicons-round-2403
Pfizer’s $1B Pill Problem

3 months ago

Premium Price Target: $700 (19% upside)

materialicons-round-2403
Eli Lilly: The Biggest Threat to Ozempic

More than 1 year ago

Premium Price Target: $10 (25% upside)

materialicons-round-2403
MorphoSys: A New Biotech Play

More than 1 year ago

Premium Price Target: $44 (30% upside)

materialicons-round-2403
Intellia: Is Gene Editing The Future of Medicine?

More than 1 year ago

Premium

materialicons-round-2403
Eli Lilly's Chronic Pincer Move

More than 1 year ago

Premium Price Target: $554 (18% upside)

materialicons-round-2403
Elevance Health: Profiting from the Wealthiest Generation

More than 1 year ago

Premium

materialicons-round-2403
Shockwave: The Sleeper in Biotech

More than 1 year ago

Premium

materialicons-round-2403
Evotec: The Best AI Healthcare Play

More than 1 year ago

Premium Price Target: $88 (19% upside)

materialicons-round-2403
AstraZeneca's AI Cancer Missiles

More than 1 year ago

Premium Price Target: $483 (15% upside)

materialicons-round-2403
How Eli Lilly is Abolishing Obesity

More than 1 year ago

Premium Price Target: $140 (21% upside)

materialicons-round-2403
Merck's Secret Weapon Against Cancer

More than 1 year ago

Premium Price Target: $340 (16% upside)

materialicons-round-2403
Intuitive Surgical: The Right Growth at the Right Time

More than 1 year ago

Premium

materialicons-round-2403
Illumina: A Famous Activist Coming Aboard

More than 1 year ago

Premium

materialicons-round-2403
Zoetis: Diversified and Poised for Growth

More than 1 year ago

Premium

materialicons-round-2403
Merck: Getting Closer To Solving Cancer

2 years ago

Premium

materialicons-round-2403
Intuitive Surgical: A Strong Return to Medical Normal

2 years ago

Premium

materialicons-round-2403
Eli Lilly: The Biggest Healthcare Advancement In A Decade

2 years ago

Premium

materialicons-round-2403
Illumina is About to Corner the DNA Market

2 years ago

Premium

materialicons-round-2403
Biogen: A Crossroads to Complete our Pharma Trifecta

2 years ago

Premium Price Target: $388 (28% upside)

materialicons-round-2403
Eli Lilly: A Solid Discount Before the Big Show

2 years ago

Premium Price Target: $689 (21% upside)

materialicons-round-2403
Thermo Fischer Scientific: Pivoting to Growth

3 years ago

Premium Price Target: $342 (20% upside)

materialicons-round-2403
Eli Lilly: Defeating America's Biggest Health Crisis

3 years ago